Tiny Tioga attracts $10m and new investor for Phase III asimadoline clinical trial
This article was originally published in Scrip
Executive Summary
The four-person virtual biotechnology company Tioga Pharmaceuticals Inc. gained another $10 million in a Series B equity financing to fund its ongoing Phase III clinical trial for asimadoline to treat diarrhoea-predominant irritable bowel syndrome (D-IBS).